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Summary Purpose: To determine the safety, in our practice, of allowing patient pref-
erence to inﬂuence the timing of antiepileptic drug (AED) reduction, once they be-
came seizure-free after anterior temporal lobectomy (ATL). Methods: Thirty patients
underwent anterior temporal lobectomy for medically intractable complex partial
epilepsy at Loma Linda University Medical Center between December 1st 1991 and
November 30th 2001. Timing of AED reduction in seizure-free patients was based
on patient request. A review of patient records noted seizure status, duration from
surgery to AED reduction, AED side effects, seizure recurrence and whether control
was regained. Results: Twenty-four (80%) of the 30 patients became seizure-free on
their preoperative AEDs after initial ATL; three additional patients after a second op-
eration. AEDs were not reduced in the reoperated patients, the three patients who
did not become seizure-free, and in two patients who asked to increase AEDs to con-
trol auras. Thus, AEDs were reduced in 22 of the 27 seizure-free patients. Patients
were followed an average of 3.4± 2.7 (mean± standard deviation) years. AED reduc-
tion was initiated 4.6± 7.2 months (range 0—27 months) after surgery. Polytherapy
use decreased from 54% preoperatively to 18% at last follow up. Seizures recurred
in six patients (27% of 22); three became seizure-free after AED adjustments. Con-
clusions: In our practice, using an individualized approach to AED reduction follow-
ing successful epilepsy surgery resulted in early reduction in AEDs. Our data suggest
that early AED reduction can be performed safely and without undue risk of seizure
recurrence.
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Introduction
Temporal lobe epilepsy affects 800,000 patients
in the United States1 with 100,000 of these es-
timated to be surgical candidates.2 The annual
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rate for epilepsy surgery in the US is estimated
to be 1500 patients.3 Surgery results in better
seizure control, a signiﬁcant reduction in total
number of antiepileptic drugs (AEDs) required,
and in an increased number of patients off AEDs
altogether.4
Improvement is seen regardless of age, though
with a trend towards better outcome with ear-
lier intervention.5 Complex partial epilepsy aris-
ing from a temporal lobe is the most common
form of medically intractable epilepsy amenable
to surgery–—anterior temporal lobectomy (ATL).
Worldwide, following ATL, a seizure-free status is
achieved in approximately 68% of patients, and
‘‘worthwhile’’ improvement in another 24%.6 A
randomized, controlled trial in Canada recently
conﬁrmed a signiﬁcant advantage of surgical over
medical treatment for intractable temporal-lobe
epilepsy, both in freedom from seizures and in
quality of life.3
The primary goal of surgery is a seizure-free
status, which is the most important determinant
of patients’ quality of life after surgery. A sec-
ondary goal is reduction in number and dosage of
AEDs, in order to reduce the burden of their side
effects. A retrospective study in 93 patients re-
ported a reduction in polytherapy (two or more
AEDs taken by a patient) from 78% preoperatively
to 47% at 6 months, 18% at 12 months, and 14%
at 24 months.7 A prospective, randomized study
of 40 patients, comparing continuation of pre-
operative AEDs to conversion to carbamazepine
monotherapy following surgery, showed no differ-
ence in seizure frequency during the ﬁrst year.2
A retrospective study of 210 consecutive patients
in which AEDs were discontinued in 84 patients
and reduced in 96 patients, showed emergence
of seizures in 14% versus 3% at 2 years and 36%
versus 7% at 5 years following surgery, showing an
increased risk of recurrence in those who com-
pletely discontinued their AEDs. Risk of subse-
quent seizure was also increased in patients with
a normal preoperative MRI scan. Interestingly, the
seizure-free duration after surgery did not appear
to impact the risk of subsequent seizures.8 We
had shown previously that recurrence of seizures
within two months after surgery predicted a
non-seizure-free status 2 years after surgery.9
Thus, we had reason to expect that patients in
whom seizures did not recur within two months of
surgery would have a good prognosis for remaining
seizure-free.
We report a retrospective review of the safety,
in our practice, of allowing patient preference to
inﬂuence the timing of AED reduction, once they
became seizure-free after ATL.
Methods
Thirty patients underwent ATL for medically in-
tractable complex partial epilepsy at Loma Linda
University Medical Center (LLUMC) from December
1991 to November 2001.
The LLUMC Institutional Review Board approved
a retrospective review of patient records and a
mailed patient questionnaire. We collected de-
scriptive data of the patients, their outcomes,
and the timing and results of AED reduction in
patients rendered seizure-free (Engel’s Classiﬁca-
tion of Postoperative Outcome10 Class 1A or 1B)
by ATL.
A speciﬁc protocol for AED reduction or with-
drawal was not followed. The timing of medication
adjustments in seizure-free patients was inﬂuenced
to varying extents by patient preference and con-
tinued until patients considered their condition op-
timally managed.
For the purpose of this review, patients were
considered ‘‘seizure-free’’ if they did not experi-
ence complex partial or generalized tonic-clonic
seizures while taking the medications as prescribed
from the time of surgery until AED reduction was
initiated or until the most recent clinic or mail
follow-up.
Results
Twenty-four of the 30 patients became seizure-free
on their preoperative AEDs after the ﬁrst re-
section (80%). Three additional patients became
seizure-free after a second surgery, for a total
of 27 seizure-free patients (90%). AEDs were not
reduced in the three patients who required ad-
ditional surgery and in two other patients who
asked to increase AEDs to control simple partial
seizures. Consequently, AEDs were reduced in the
remaining 22 patients (81% of the 27 seizure-free
patients).
The entire group of 30 patients were followed
an average of 3.4± 2.7 (mean± S.D.) years. In
the medication reduction group, follow up aver-
aged 3.2± 2.7 (mean± S.D.) years after surgery,
with three (13%) followed less than 1 year, seven
(32%) from 1 to 2 years, ﬁve (23%) for 2 to 5
years, and seven (32%) for more than 5 years.
The three followed for less than 1 year were
seizure-free with AED reductions at last available
follow-up.
There were six patients who did not become
seizure-free; three became seizure-free after a
second operation. The postoperative seizures oc-
curred within 2 months of surgery in four patients
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Table 1 Characteristics of 30 patients who under-
went ATL at LLUMC, comparing Group 1 (22 patients
seizure-free with AED reduction) with Group 2 (3
re-operated, 3 not seizure-free, 2 requesting AED in-
crease for a total of 8) and with the entire population
of 30.
Baseline patient
characteristics
Group 1 Group 2 Entire
group
Number of patients 22 (73) 8 (27) 30 (100)
Age at surgery
Mean 29 30 30
Range 10—51 18—56 10—56
Gender
Women 13 (59) 5 (62) 18 (60)
Men 9 (41) 3 (38) 12 (40)
Seizure frequency preoperatively
1—4 per month 7 (32) 2 (25) 9 (30)
5—9 per month 2 (9) 2 (25) 4 (13)
10—19 per month 5 (23) 1 (12) 6 (46)
>20 per month 8 (36) 3 (38) 11 (37)
Language dominance of operated side
Dominant 9 (41) 2 (25) 11 (37)
Non-dominant 13 (59) 6 (75) 19 (63)
Pathology
MTS 11 (50) 5 (63) 16 (53)
Tumor 5 (23) 1 (13) 6 (20)
VM 4 (18) 0 (0) 4 (13)
Trauma/
infection/scar
2 (9) 2 (25) 4 (13)
MRI
Normal 5 (23) 4 (50) 9 (30)
Abnormal 17 (77) 4 (50) 21 (70)
MTS: mesial temporal sclerosis; VM: vascular
malformation.
and within 12 months in two additional patients.
Seizure recurrence from time of surgery averaged
3.8± 5.1 (mean± S.D.) months.
Table 1 compares Group 1, the seizure-free group
of 22 who underwent AED reduction, with Group
2, which includes the three re-operated patients
(now seizure-free), the two patients who requested
AED increase to control their aura, and the three
patients who never achieved a seizure-free state
(continuing to have rare complex partial or gen-
eralized seizures). The characteristics of the two
groups are similar except that the presurgical MRI
results showed an abnormality in 17 (77%) of Group
1 compared to 4 (50%) of Group 2 (see Table 1).
The nature of the medication intolerance leading
to AED reduction was as follows: cognitive effects in
ﬁve cases, somnolence in two cases; fatigue, nau-
sea, decreased libido, and depression one case of
each. In three cases patients took the initiative to
reduce their medication.
AED reduction was initiated in the 22 patients at
a mean of 4.6± 7.2 (mean± S.D.) months (range
0—27 months) after surgery. This occurred within 1
month of surgery in nine patients (41% of the 22 pa-
tients with AED reduction), in 1—2 months in four
(18%), in 2—4 months in three (14%), in 4—6 months
in two (10%), 6—12 months in two (10%), and 12—24
months in two (10%). As a result, polytherapy use
dropped in these 22 patients from 12 (54%) preoper-
atively to 9 (41%) 2 months postoperatively, 4 (18%)
at 6 months, 4 (18%) at 12 months, and at the last
available follow-up. While not encouraged to do so,
AEDs were discontinued after 24 months in two pa-
tients by their request. They remained seizure-free
at follow-up, respectively, 2 and 8 months following
discontinuation.
Seizures emerged in 6 (27%) of 22 patients
seizure-free patients when AEDs were reduced.
Seizures stopped in three patients after alternative
AEDs were introduced or, less frequently, existing
AEDs were increased (though not to their previous
levels). Medication adjustment continues in the
three other patients.
Discussion
Once patients became seizure-free, they were
unwilling to tolerate the same burden of AED
side effects that they had accepted when they
were having uncontrolled seizures preoperatively.
Our protocol of AED reduction initiated in re-
sponse to our patients’ requests lead to earlier
reduction than the historical 1—2-year waiting pe-
riod following surgery–—the majority within 2—4
months. The majority (73%) underwent early AED
reduction without seizure recurrence. Seizures
recurred in 27%, and remained incompletely con-
trolled in half (three patients or 14%). This ﬁnd-
ing concurs with the ﬁnding of Schiller et al.8
that timing of AED reduction (or seizure-free du-
ration) does not appear to be a risk factor for
recurrence.
Looking back at our data, none of the demo-
graphic, clinical or surgical pathology data dis-
tinguished the subgroup who became seizure-free
and in whom AEDs could be reduced from the re-
maining patients or the entire surgical group. This
may be due to the small numbers, to patient se-
lection, to our deﬁnition, applied retrospectively,
of the seizure-free status for the purpose of initi-
ating medication reduction, and to the weight we
gave to patient preference regarding the timing of
medication reduction.
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Similarly, the 90% seizure-free number for our
patient population cannot be compared to num-
bers in the literature because of the dynamic,
time-dependent, way it is derived. The number
includes three patients who required a second op-
eration to become seizure-free, and, in those pa-
tients in whom AEDs were reduced, is based on an
observation period extending only up to the time
of initiation of medication reduction. If the three
patients who required a second operation and the
three patients who relapsed after medication re-
duction and have not been rendered seizure-free
were classiﬁed as ‘‘not seizure-free’’, our num-
bers for the results of the ﬁrst operation would be
comparable to the general average.
Further, under-reporting of seizures by patients
who undergo epilepsy is recognized, and was re-
ﬂected recently in our own experience with one of
two patients in the medication reduction group in
whom seizures emerged.
Thus, inferences from these data should be
constrained to the following: early, gradual,
post-operative AED reduction in patients who be-
come seizure-free after ATL may be accomplished
with relative safety to the degree needed to ame-
liorate AED side effects.
Looking forward, application to our clinical prac-
tice includes: (1) an 8 in 10 success rate, (2) a
willingness to reduce AEDs early after successful
surgery (4 months on average) with a 1 in 4 risk of
seizure recurrence, and (3) 1 in 2 likelihood of re-
gaining a seizure-free state in those recur.
We currently view ATL as an important tool
in the armamentarium to achieve a seizure-free
status in selected patients with complex partial
epilepsy, and do not subscribe to a predeﬁned
period of post-surgical observation before initiat-
ing medication changes. A particular advantage
to patients of early AED adjustment is that it is
easier to deal with the possibility of temporary
emergence of seizures before patients begin or
resume driving. Our data permit us to provide
our patients with more precise estimates of the
likelihood of the various postoperative and AED re-
duction outcomes. We introduce AED modiﬁcations
early following surgery, taking into account the
patients’ perspectives, to achieve seizure-freedom
with tolerable or no medication-related side
effects.
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